Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment

Kühlkamp, Volker; Mewis, Christian; Suchalla, Ralph; Mermi, Johann; Dörnberger, Volker; Seipel, L

doi:10.1016/s0167-5273(99)00055-8

Cited by 35 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a retrospective analysis of patients with biphasic transvenous defibrillators, the average DFT of patients taking sotalol was 17Ϯ6.1 J compared with 14.4Ϯ7.2 J in patients not receiving antiarrhythmic drug therapy. 29 The present study is thus the first randomized evaluation and demonstrates that in patients with modern ICDs, the effects of sotalol on DFT are similar to those of conventional ␤-blockers without class III antiarrhythmic properties.…”

Section: Antiarrhythmic Drug-associated Changes In Dftmentioning

confidence: 52%

See 1 more Smart Citation

Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold

et al. 2006

View full text Add to dashboard Cite

Background-Many patients with implanted cardioverter defibrillators (ICDs) receive adjunctive antiarrhythmic drug therapy, most commonly amiodarone or sotalol. The effects of these drugs on defibrillation energy requirements have not been previously assessed in a randomized controlled trial. Methods and Results-The Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) trial was a randomized clinical trial evaluating the efficacy of amiodarone plus ␤-blocker and sotalol versus ␤-blocker alone for reduction of ICD shocks. Within OPTIC, a prospectively designed substudy evaluated the effects of the 3 treatment arms on defibrillation energy requirements. Defibrillation thresholds (DFTs) were measured (binary step-down protocol) at baseline and again after 8 to 12 weeks of therapy in 94 patients, of whom 29 were randomized to receive ␤-blocker therapy (control group), 35 to amiodarone plus ␤-blocker, and 30 to sotalol. In the control group, the mean DFT decreased from 8.77Ϯ5.15 J at baseline to 7.13Ϯ3.43 J (Pϭ0.027); in the amiodarone group, DFT increased from 8.53Ϯ4.29 to 9.82Ϯ5.84 J (Pϭ0.091). In the sotalol group, DFT decreased from 8.09Ϯ4.81 to 7.20Ϯ5.30 J (Pϭ0.21). DFT changes in the ␤-blocker and the amiodarone group were significantly different (Pϭ0.006). In all patients, adequate safety margins for defibrillation were maintained. No clinical variable predicted baseline DFT or changes in DFT on therapy. Conclusion-Although amiodarone increased DFT, the effect size with modern ICD systems is very small. Therefore, DFT reassessment after the institution of antiarrhythmic drug therapy with amiodarone or sotalol is not routinely required.

show abstract

Section: Antiarrhythmic Drug-associated Changes In Dftmentioning

confidence: 52%

“…29,30 Hodgson et al 30 studied 102 patients receiving active-can biphasic ICDs, 11 of whom also received amiodarone. They reported a mean DFT of 9.3Ϯ4.8 J in patients without compared with 9.3Ϯ3.6 J in those with amiodarone therapy.…”

Section: Antiarrhythmic Drug-associated Changes In Dftmentioning

confidence: 99%

Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold

et al. 2006

View full text Add to dashboard Cite

show abstract

“…[13][14][15] The Nippon ICD Plus Pharmachologic Option Necessity (NIPPON) pre-study demonstrated that the VT/VF event rate in ICD patients with class I agent adjunctive therapy was significantly higher than that in patients with amiodarone. 16 Furthermore, no fatal side-effect of amiodarone was observed in the NIPPON pre-study.…”

Section: Methods and Resultsmentioning

confidence: 99%

Japanese Randomized Trial for Investigation of a Combined Therapy of Amiodarone and Implantable Cardioverter Defibrillator in Patients With Ventricular Tachycardia and Fibrillation

Kurita

Mitamura

Aizawa

et al. 2006

Circ J

View full text Add to dashboard Cite

“…Amiodarone is an antiarrhythmic agent (see Kühlkamp et al [1999]) which can be administered either intravenously (i.v.) or orally.…”

Section: Feedback Control Of Amiodarone Administrationmentioning

confidence: 99%

Controlled Drug Administration by a Fractional PID

Sopasakis

Sarimveis

2014

IFAC Proceedings Volumes

View full text Add to dashboard Cite

Amiodarone is an antiarrhythmic drug that exhibits highly complex and nonexponential dynamics whose controlled administration has important implications for its clinical use especially for long-term therapies. Its pharmacokinetics has been accurately modelled using a fractional-order compartmental model. In this paper we design a fractional-order PID controller and we evaluate its dynamical characteristics in terms of the stability margins of the closed loop and the ability of the controlled system to attenuate various sources of noise and uncertainty.

show abstract

Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment

Cited by 35 publications

References 22 publications

Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold

Effect of Amiodarone and Sotalol on Ventricular Defibrillation Threshold

Japanese Randomized Trial for Investigation of a Combined Therapy of Amiodarone and Implantable Cardioverter Defibrillator in Patients With Ventricular Tachycardia and Fibrillation

Controlled Drug Administration by a Fractional PID

Contact Info

Product

Resources

About